24/7 Market News Snapshot 08 October, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)
DENVER, Colo., 08 October, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
bioAffinity Technologies, Inc. is making significant strides in the biotechnology sector with its commitment to revolutionize early-stage cancer detection through innovative noninvasive testing. The company has recently announced a definitive agreement to offer 720,000 shares of its common stock at $2.50 per share, anticipating gross proceeds of approximately $1.8 million. This registered direct offering is expected to close shortly, pending customary conditions. Proceeds from this endeavor will primarily support working capital and bolster operations for its flagship product, CyPath® Lung, a pioneering test designed for lung cancer detection.
Today, shares of bioAffinity Technologies opened at $3.14, reflecting a robust bullish sentiment as the stock experienced an impressive surge, climbing over 20% at its peak during a volatile trading session. The stock is currently trading at $2.945, with an extraordinary 34.77 million shares exchanged, which indicates heightened investor interest and a strong market presence.
As bioAffinity continues to navigate the complexities of the biotech landscape, this financing initiative is crucial for its operational and developmental pursuits. WallachBeth Capital LLC is acting as the sole placement agent for this offering, which falls under a prior shelf registration statement filed with the U.S. Securities and Exchange Commission. A prospectus supplement detailing this offering will also be made available to investors.
bioAffinity Technologies reinforces its commitment to enhancing cancer diagnostics, emphasizing that their noninvasive solutions could significantly improve early detection rates. With this strategic move, the company not only aims to gather essential capital but also to further its mission of innovating healthcare solutions that have the potential to save lives. The market will be keenly observing the subsequent developments as bioAffinity continues to lead on the forefront of cancer detection technology.